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placebo-treated patients, were 42 - 61% less likely to have 
significant arterial calcification (as measured by computed 
tomography).2 These publications are in stark contrast to earlier 
publications by the same investigators that implied HT as a 
cause of CAD, without taking into account that this did not 
apply to the typical patient, who initiates HT at the age of  
50 - 59 years.3
Dr Rapeport further falsely assumes that SAMS promotes 
the use of HT for the prevention of CAD, even though it is 
not included in the list of approved indications in the revised 
guidelines. We maintain our position that if the only aim of 
treatment is protection against CAD, HT is an inappropriate 
choice in view of other proven methods. However, it is 
important to be able to assure the patient in the age group 50 - 
59 years, who starts HT for the control of vasomotor symptoms 
or the prevention or treatment of osteoporosis, not only that 
HT will not cause CAD, but that protection can be expected. 
This also needs to be taken into account when deciding on 
termination of treatment.
We stand by our statement that the initiation of HT for the 
indications as provided is safe for the patient in the age group 
50 - 59 years and that the small risk of any complication can be 
further reduced by using the lowest effective dose.
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‘Opi-phobia’ among doctors leads to  
unnecessary suffering
To the Editor: Francois Venter and Chris Bateman are to be 
commended on this piece.1 Basic training of South African 
doctors and nurses in palliative care has been poor.  Therefore 
few have raised their voices to improve palliative care, despite 
the great need for it in a developing country where many 
patients present with far advanced disease.  This applies 
particularly to people with HIV because of denial and stigma.
An important step towards the development of good general 
palliative care in Australia and the UK has been the formation 
of departments of palliative care in teaching hospitals, through 
which all students must rotate during their training.  I suggest 
that pharmacology students also have a short rotation.  With 
the enormous need for such care, it seems an urgent priority to 
establish such departments in all our teaching hospitals. These 
should also bring past graduates up to speed in this discipline.
Another serious public sector hospital problem is the lack 
of effective links between district hospitals and community 
structures offering home-based care.  Too often, medical 
staff end up saying to patients, ‘There is nothing more that 
we can do for you’, because the doctor has decided cure is 
not possible.  In most cases, no thought is given to linking 
patients to community carers, or to empowering the carers 
with medications to reduce the suffering of their last days. No 
help in controlling symptoms is provided to home-based 
carers who appeal to district clinics when the scheduled 
drugs needed are not available to clinic staff.  This has two 
effects. Firstly, hospital staff are never really confronted with 
the patient’s palliative care needs, so they never grow in that 
expertise. Secondly, there is an assumption that palliative care 
in HIV is simple (which it is not), just as the rest of the medical 
care of people with HIV is difficult and requires considerable 
experience and expertise.
A solution to this problem could be the development of 
palliative care facilities in every district hospital, staffed by 
medical and nursing staff who are part of the training team 
of home-based carers in the district.  They could assess the 
patient’s palliative needs, access the necessary medications, 
and link the patient and family to a designated carer, or non-
governmental organisation.  They should also identify patients 
with HIV wrongly consigned to terminal care when they have 
a manageable infectious condition.  Such a facility could have 
regular follow-up clinics in each of the district clinics, and be 
empowered to carry and dispense the necessary scheduled 
drugs. This should be a high-priority project for co-operation 
between district health services and the medical staff of every 
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Achieving the Millennium Develop-
ment Goals in sub-Saharan Africa  
To the Editor: The UN has released a mid-term report on 
progress towards achieving the Millennium Development 
Goals (MDG), eight pro-poor goals contained in the 
Millennium Declaration of 2000, to be achieved by 2015.1 
It paints a gloomy picture of health in sub-Saharan Africa. 
Child mortality rates declined globally, but the improvement 
was uneven, with sub-Saharan Africa recording the highest 
rate and the slowest pace of progress. In 1990 and 2005 in 
sub-Saharan Africa, 185 and 166 children respectively died, 
mainly from preventable causes, before their 5th birthday for 
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every 1 000 live births, a mere 10% reduction in 16 years. The 
corresponding figures for North Africa were 88 and 35 (i.e. 
60% reduction). In addition, a woman’s lifetime risk of dying 
during pregnancy and childbirth was 1 in 16 in sub-Saharan 
Africa; compared with 1 in 3 800 in the developed world. Most 
maternal deaths in sub-Saharan Africa resulted from maternal 
haemorrhage, hypertensive disorders of pregnancy, sepsis, 
abortion, and obstructed labour.2,3 Most of these deaths could 
have been prevented through appropriate reproductive health 
services before, during and after pregnancy, and through life-
saving interventions when complications occur.4,5 
Sub-Saharan Africa can increase its pace towards achieving 
health MDG if efforts to prevent death and disability are 
tailored to local conditions, given that the causes of death and 
disability vary considerably.2,3,6 Choice of health interventions 
and policies should be based on solid scientific evidence, and, 
where it is lacking, we must invest in research.7 Such well-
informed selection and implementation of effective health care 
interventions and policies requires close collaboration between 
policy-makers and researchers. 
The SUPPORT (SUPporting Policy-relevant Reviews and 
Trials) Collaboration is an example of cooperative partnership 
between researchers and policy-makers in low- and middle-
income countries, which started in October 2006. SUPPORT 
(www.support-collaboration.org) involves partner institutions 
in sub-Saharan Africa, Latin America, Europe and North 
America, and aims to improve the use of reliable research 
evidence in decisions on maternal and child health, and to 
help fill in the gaps where there is a lack of rigorous evidence. 
The partner institutions (including the Medical Research 
Council of South Africa) are preparing summaries of current 
best evidence on the effectiveness of relevant interventions in 
a way that is easily accessible to decision makers, developing 
tools to support access to and use of research evidence to 
inform policy decisions, supporting the conduct of pragmatic 
trials of interventions when reliable evidence is lacking, and 
exploring appropriate ways to disseminate these tools and 
provide support for the appropriate use of research evidence. 
The structured summaries will be available by December 2007 
and SUPPORT partners conducted a policy-maker workshop 
in Rosario (Argentina) in November 2006 and have planned 
others in Harare (Zimbabwe) and Cape Town (South Africa) 
in September and November 2007 respectively. Workshops 
comprise interactive presentations and small group sessions 
during which policy-makers develop skills on how to frame 
a health problem, identify a systematic review or trial that 
addresses the problem, and assess the quality and local 
applicability of the systematic review or trial. Each workshop is 
planned and facilitated by both policy-makers and researchers, 
ends with an evaluation, and empowers policy-makers to 
become informed users of research-based evidence. This 
knowledge-translation project provides a model of how multi-
national collaborations can be configured and how efficiencies 
can be gained from cross-continental linkages.  
C S Wiysonge 
T Young
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Why no autopsies on marathon deaths?
To the Editor: The July 2007 SAMJ featured a report on 
the deaths of two Comrades Marathon runners.1  I agree 
with Mayosi of Groote Schuur Hospital that postmortem 
examinations should be performed on such cases to establish 
the cause of death with certainty, in so far as it is possible, 
because of implications for the surviving next of kin. 
We expected that the Forensic Pathology Services in Durban 
would receive these cases, but neither was referred.  Both 
deaths can be considered unexpected and unexplained sudden 
deaths, since there are no clear clinical diagnoses (owing to 
very short survival of only one of them) and both individuals 
were relatively young.  However, the decision to request 
an autopsy is the duty of the clinician responsible for the 
patient.  It is likely that both these deaths were considered and 
registered as natural deaths.
There is capacity for diagnostic autopsy examinations on 
sudden unexpected deaths mainly in the academic forensic 
pathology centres.  Where the source of the case is not a 
public establishment, there is little provision in the academic 
anatomical pathology unit served by that establishment (now 
under the National Health Laboratory Service) for a diagnostic 
autopsy.  In these cases, one was declared dead in the medical 
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